Cargando…

The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications

Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Férir, Geoffrey, Petrova, Mariya I., Andrei, Graciela, Huskens, Dana, Hoorelbeke, Bart, Snoeck, Robert, Vanderleyden, Jos, Balzarini, Jan, Bartoschek, Stefan, Brönstrup, Mark, Süssmuth, Roderich D., Schols, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665789/
https://www.ncbi.nlm.nih.gov/pubmed/23724015
http://dx.doi.org/10.1371/journal.pone.0064010
_version_ 1782271302497730560
author Férir, Geoffrey
Petrova, Mariya I.
Andrei, Graciela
Huskens, Dana
Hoorelbeke, Bart
Snoeck, Robert
Vanderleyden, Jos
Balzarini, Jan
Bartoschek, Stefan
Brönstrup, Mark
Süssmuth, Roderich D.
Schols, Dominique
author_facet Férir, Geoffrey
Petrova, Mariya I.
Andrei, Graciela
Huskens, Dana
Hoorelbeke, Bart
Snoeck, Robert
Vanderleyden, Jos
Balzarini, Jan
Bartoschek, Stefan
Brönstrup, Mark
Süssmuth, Roderich D.
Schols, Dominique
author_sort Férir, Geoffrey
collection PubMed
description Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spectrum activity against HIV and HSV in vitro, studied its mechanism of action and evaluated potential microbicidal applications. LabyA1 exhibited a consistent and broad anti-HIV activity (EC(50)s: 0.70–3.3 µM) and anti-HSV activity (EC(50)s: 0.29–2.8 µM) in cell cultures. LabyA1 also inhibited viral cell-cell transmission between persistently HIV-infected T cells and uninfected CD4(+) T cells (EC(50)∶2.5 µM) and inhibited the transmission of HIV captured by DC-SIGN(+)-cells to uninfected CD4(+) T cells (EC(50)∶4.1 µM). Time-of-drug addition studies revealed that LabyA1 acts as an entry inhibitor against HIV and HSV. Cellular and virus binding studies combined with SPR/FLIPR technology showed that LabyA1 interacted with the HIV envelope protein gp120, but not with the HIV cellular receptors. LabyA1 also demonstrated additive to synergistic effects in its anti-HIV-1 and anti-HSV-2 activity with anti(retro)viral drugs in dual combinations such as tenofovir, acyclovir, saquinavir, raltegravir and enfuvirtide. LabyA1 can be considered as a novel lead peptide as it had profound antiviral activity against HIV and HSV. Pre-treatment of PBMCs with LabyA1 neither increased the expression of the activation markers CD69 and CD25, nor enhanced HIV replication, nor significantly induced various inflammatory cytokines/chemokines. LabyA1 also did not affect the growth of vaginal Lactobacilli populations. Based on the lack of toxicity on the vaginal Lactobacillus strains and its synergistic/additive profile in combination with clinically approved anti(retro)virals, it deserves further attention as a potential microbicide candidate in the prevention of sexual transmitted diseases.
format Online
Article
Text
id pubmed-3665789
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36657892013-05-30 The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications Férir, Geoffrey Petrova, Mariya I. Andrei, Graciela Huskens, Dana Hoorelbeke, Bart Snoeck, Robert Vanderleyden, Jos Balzarini, Jan Bartoschek, Stefan Brönstrup, Mark Süssmuth, Roderich D. Schols, Dominique PLoS One Research Article Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spectrum activity against HIV and HSV in vitro, studied its mechanism of action and evaluated potential microbicidal applications. LabyA1 exhibited a consistent and broad anti-HIV activity (EC(50)s: 0.70–3.3 µM) and anti-HSV activity (EC(50)s: 0.29–2.8 µM) in cell cultures. LabyA1 also inhibited viral cell-cell transmission between persistently HIV-infected T cells and uninfected CD4(+) T cells (EC(50)∶2.5 µM) and inhibited the transmission of HIV captured by DC-SIGN(+)-cells to uninfected CD4(+) T cells (EC(50)∶4.1 µM). Time-of-drug addition studies revealed that LabyA1 acts as an entry inhibitor against HIV and HSV. Cellular and virus binding studies combined with SPR/FLIPR technology showed that LabyA1 interacted with the HIV envelope protein gp120, but not with the HIV cellular receptors. LabyA1 also demonstrated additive to synergistic effects in its anti-HIV-1 and anti-HSV-2 activity with anti(retro)viral drugs in dual combinations such as tenofovir, acyclovir, saquinavir, raltegravir and enfuvirtide. LabyA1 can be considered as a novel lead peptide as it had profound antiviral activity against HIV and HSV. Pre-treatment of PBMCs with LabyA1 neither increased the expression of the activation markers CD69 and CD25, nor enhanced HIV replication, nor significantly induced various inflammatory cytokines/chemokines. LabyA1 also did not affect the growth of vaginal Lactobacilli populations. Based on the lack of toxicity on the vaginal Lactobacillus strains and its synergistic/additive profile in combination with clinically approved anti(retro)virals, it deserves further attention as a potential microbicide candidate in the prevention of sexual transmitted diseases. Public Library of Science 2013-05-28 /pmc/articles/PMC3665789/ /pubmed/23724015 http://dx.doi.org/10.1371/journal.pone.0064010 Text en © 2013 Férir et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Férir, Geoffrey
Petrova, Mariya I.
Andrei, Graciela
Huskens, Dana
Hoorelbeke, Bart
Snoeck, Robert
Vanderleyden, Jos
Balzarini, Jan
Bartoschek, Stefan
Brönstrup, Mark
Süssmuth, Roderich D.
Schols, Dominique
The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title_full The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title_fullStr The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title_full_unstemmed The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title_short The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
title_sort lantibiotic peptide labyrinthopeptin a1 demonstrates broad anti-hiv and anti-hsv activity with potential for microbicidal applications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665789/
https://www.ncbi.nlm.nih.gov/pubmed/23724015
http://dx.doi.org/10.1371/journal.pone.0064010
work_keys_str_mv AT ferirgeoffrey thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT petrovamariyai thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT andreigraciela thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT huskensdana thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT hoorelbekebart thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT snoeckrobert thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT vanderleydenjos thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT balzarinijan thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT bartoschekstefan thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT bronstrupmark thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT sussmuthroderichd thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT scholsdominique thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT ferirgeoffrey lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT petrovamariyai lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT andreigraciela lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT huskensdana lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT hoorelbekebart lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT snoeckrobert lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT vanderleydenjos lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT balzarinijan lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT bartoschekstefan lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT bronstrupmark lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT sussmuthroderichd lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications
AT scholsdominique lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications